
Merck (MRK) Stock Forecast & Price Target
Merck (MRK) Analyst Ratings
Bulls say
Merck & Co is poised for strong growth through the next decade, with key products such as Keytruda, Gardasil, and a strong pipeline in the works. Particularly, the CADENCE presentation provided robust data that demonstrates the potential for Merck's Winrevair franchise to drive significant sales growth. Additionally, the company's focus on sustainability and their plan to reinvest in strategic growth areas are indicative of a company with a strong long-term outlook.
Bears say
Merck & Co is facing significant challenges in the highly competitive pharmaceutical industry, as it tries to gain market share for its blockbuster drugs Keytruda and Gardasil while facing potential risks in its clinical trials. They recently reported exceptional results for their TTCW endpoint, but it remains to be seen if these positive results can be sustained. Additionally, the company's integration of sustainability into its business operations is commendable, but it remains to be seen if it will have a meaningful impact on their financial performance.
This aggregate rating is based on analysts' research of Merck and is not a guaranteed prediction by Public.com or investment advice.
Merck (MRK) Analyst Forecast & Price Prediction
Start investing in Merck (MRK)
Order type
Buy in
Order amount
Est. shares
0 shares